EGFR and breast carcinoma: In terms of inhibition of angiogenesis, a study involving head, neck, and breast carcinomas found that EGCG at 30 μg/mL reduced VEGF production by interfering with epidermal growth factor receptor (EGFR)-related pathways [141].